Key points
- Loss after tax attributable to members increased by 184% to $1,352,352
- Successful renewal of orphan drug designation for Exenatide in Europe for TBI
- Expanded preclinical research program with Tessara Therapeutics in ADBrain platform
- No dividends were paid or recommended by the Directors
- De-registration of 100% owned UK subsidiary Invex Therapeutics Ltd (UK)
Full summary
INVEX Therapeutics Ltd's FY2026 report highlights a substantial increase in loss after tax attributable to members, up by 184% to $1,352,352, primarily driven by higher research and development costs. The company successfully renewed its orphan drug designation for Exenatide in Europe for Traumatic Brain Injury (TBI), complementing its other designations in Idiopathic Intracranial Hypertension. A significant development was the expanded preclinical research program with Tessara Therapeutics, focusing on Exenatide's potential in Alzheimer's Disease (AD) treatment, including benchmarking against another GLP-1 receptor agonist and evaluating combination regimens. The company also de-registered its UK subsidiary. No dividends were paid or recommended.